Bioatla Inc (NASDAQ:BCAB) — Market Cap & Net Worth
Market Cap & Net Worth: Bioatla Inc (BCAB)
Bioatla Inc (NASDAQ:BCAB) has a market capitalization of $11.14 Million ($11.14 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26608 globally and #5309 in its home market, demonstrating a -17.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioatla Inc's stock price $4.27 by its total outstanding shares 74263742 (74.26 Million). Analyse Bioatla Inc cash conversion from operations to see how efficiently the company converts income to cash.
Bioatla Inc Market Cap History: 2020 to 2026
Bioatla Inc's market capitalization history from 2020 to 2026. Data shows change from $2.53 Billion to $317.11 Million (-30.85% CAGR).
Index Memberships
Bioatla Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #767 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2516 of 3165 |
Weight: Bioatla Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bioatla Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioatla Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.99x
Bioatla Inc's market cap is 3.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.53 Billion | $429.00K | -$35.85 Million | 5887.44x | N/A |
| 2021 | $1.46 Billion | $250.00K | -$95.40 Million | 5831.19x | N/A |
| 2024 | $43.90 Million | $11.00 Million | -$69.78 Million | 3.99x | N/A |
Competitor Companies of BCAB by Market Capitalization
Companies near Bioatla Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Bioatla Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Bioatla Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Bioatla Inc's market cap moved from $2.53 Billion to $ 317.11 Million, with a yearly change of -30.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $317.11 Million | +652.16% |
| 2025 | $42.16 Million | -3.97% |
| 2024 | $43.90 Million | -75.97% |
| 2023 | $182.69 Million | -70.18% |
| 2022 | $612.68 Million | -57.97% |
| 2021 | $1.46 Billion | -42.28% |
| 2020 | $2.53 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Bioatla Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.14 Million USD |
| MoneyControl | $11.14 Million USD |
| MarketWatch | $11.14 Million USD |
| marketcap.company | $11.14 Million USD |
| Reuters | $11.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer … Read more